Fasudil ( DrugBank: Fasudil )

4 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	4
5	進行性核上性麻痺	1
7	大脳皮質基底核変性症	1
51	全身性強皮症	1

2. 筋萎縮性側索硬化症

臨床試験数 : 624 / 薬物数 : 611 - (DrugBank : 160) / 標的遺伝子数 : 172 - 標的パスウェイ数 : 225

diseases per page:

Showing 1 to 4 of 4 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05218668 (ClinicalTrials.gov)	December 22, 2021	23/11/2021	Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)	A Phase 2a Open-Label Preliminary Safety, Efficacy, and Biomarker Study of WP-0512 in Patients With ...	Amyotrophic Lateral Sclerosis	Drug: Fasudil (WP-0512)	Woolsey Pharmaceuticals	NULL	Recruiting	18 Years	75 Years	All	20	Phase 2	United States;Australia
2	EUCTR2017-003676-31-FR (EUCTR)	31/12/2019	25/04/2018	Inhibition of Rho Kinase (ROCK) with Fasudil as disease-modifying treatment for ALS	Inhibition of Rho Kinase (ROCK) with Fasudil as disease-modifying treatment for ALS	Amyotrophic lateral sclerosis MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyo ...	Trade Name: Eril® INN or Proposed INN: FASUDILHYDROCHLORIDE Other descriptive name: FASUDILHYDROCHLORI ...	Georg-August-Universität Göttingen	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	120	Phase 2	France;Germany;Switzerland
3	NCT03792490 (ClinicalTrials.gov)	February 20, 2019	28/12/2018	Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS	Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS	Amyotrophic Lateral Sclerosis	Drug: Fasudil;Drug: Placebo	University Medical Center Goettingen	NULL	Recruiting	18 Years	N/A	All	120	Phase 2	France;Germany;Switzerland
4	NCT01935518 (ClinicalTrials.gov)	September 2013	1/9/2013	A Clinical Trial of Safety and Efficacy of Fasudilin Subjects With Amyotrophic Lateral Sclerosis (AL ...	A Historical Placebo Controlled Screening Trial of Safety and Efficacy of Fasudilin Subjects With Am ...	Amyotrophic Lateral Sclerosis	Drug: Fasudil	Peking University Third Hospital	NULL	Recruiting	18 Years	70 Years	Both	10	Phase 2	China

First Previous1Next Last

5. 進行性核上性麻痺

臨床試験数 : 95 / 薬物数 : 119 - (DrugBank : 40) / 標的遺伝子数 : 65 - 標的パスウェイ数 : 108

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04734379 (ClinicalTrials.gov)	January 22, 2021	18/1/2021	Rho Kinase (ROCK) Inhibitor in Tauopathies - 1	A Phase 2a Open-Label Preliminary Safety, Tolerability, and Biomarker Study of Oral Fasudilin Patien ...	Progressive Supranuclear Palsy;Corticobasal Syndrome	Drug: Fasudil	Woolsey Pharmaceuticals	NULL	Active, not recruiting	35 Years	80 Years	All	15	Phase 2	United States

First Previous1Next Last

7. 大脳皮質基底核変性症

臨床試験数 : 18 / 薬物数 : 35 - (DrugBank : 13) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 38

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04734379 (ClinicalTrials.gov)	January 22, 2021	18/1/2021	Rho Kinase (ROCK) Inhibitor in Tauopathies - 1	A Phase 2a Open-Label Preliminary Safety, Tolerability, and Biomarker Study of Oral Fasudilin Patien ...	Progressive Supranuclear Palsy;Corticobasal Syndrome	Drug: Fasudil	Woolsey Pharmaceuticals	NULL	Active, not recruiting	35 Years	80 Years	All	15	Phase 2	United States

First Previous1Next Last

51. 全身性強皮症

臨床試験数 : 523 / 薬物数 : 608 - (DrugBank : 156) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 215

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00498615 (ClinicalTrials.gov)	April 2007	6/7/2007	A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon	Efficacy, Tolerability and Biology of a Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's ...	Raynaud;Scleroderma	Drug: Fasudil	Johns Hopkins University	NULL	Completed	18 Years	80 Years	All	17	Phase 3	United States

First Previous1Next Last

先頭へ